clinical trial · NCT04541186
Study to Explore the Efficacy and Safety of BIO89-100 (Pegozafermin) in Participants With Severe Hypertriglyceridemia
89bio, Inc.·phase2·completed·n = 86
Severe HypertriglyceridemiaPegozaferminPlacebo
brief summary
This study is designed to assess the efficacy, safety, and tolerability of different doses and dose regimens (once weekly \[QW\] or every 2 weeks \[Q2W\]), subcutaneous (SC) dosing of BIO89-100 (pegozafermin) compared to placebo in participants with severe hypertriglyceridemia (SHTG).
started
Sep 1, 2020
primary completion
May 19, 2022
completion
May 31, 2022
last updated
Jul 25, 2024
official title
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Explore the Efficacy and Safety of BIO89-100 in Subjects With Severe Hypertriglyceridemia
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol